Impact of bariatric surgery on circulating PCSK9 levels as a marker of cardiovascular disease risk: a meta-analysis

Impact of bariatric surgery on circulating PCSK9 levels as a marker of cardiovascular disease risk: a meta-analysis

Introduction This systematic review and meta-analysis focuses on PCSK9 changes in obese patients following bariatric surgery. Material and methods A systematic literature search in four databases was performed. Comprehensive Meta-Analysis (CMA) V2 software used to conduct the meta-analysis. Studies...

Full description

Bibliographic Details
Main Authors:	Tannaz Jamialahmadi, Maciej Banach, Wael Almahmeed, Prashant Kesharwani, Amirhossein Sahebkar
Format:	Article
Language:	English
Published:	Termedia Publishing House 2022-08-01
Series:	Archives of Medical Science
Subjects:	bariatric surgery low-density lipoprotein-cholesterol obesity meta-analysis pcsk9
Online Access:	https://www.archivesofmedicalscience.com/Impact-of-bariatric-surgery-on-circulating-PCSK9-levels-as-a-marker-of-cardiovascular,152685,0,2.html

Similar Items

RETRACTED ARTICLE: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

Targeting PCSK9 as a key player in lipid metabolism: exploiting the therapeutic and biosensing potential of aptamers
by: Maryam Mahjoubin-Tehran, et al.
Published: (2024-05-01)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
by: Yara Azar, et al.
Published: (2022-05-01)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.
by: Sarina Ataei, et al.
Published: (2023-01-01)

Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-07-01)

PCSK9 - A New and Potent Approach to Lowering Cholesterol
by: Thomas F. Whayne Jr.
Published: (2013-05-01)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
by: Qidi Ying, et al.
Published: (2021-02-01)

Just Price for PCSK9 Inhibitors: No less, No More
by: Khurram Nasir
Published: (2018-11-01)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-03-01)

Proteomic Signatures of Genetically Predicted and Pharmacologically Observed PCSK9 Inhibition
by: Jordan M. Kraaijenhof, et al.
Published: (2024-06-01)

Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01)

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
by: Sai Sahana Sundararaman, et al.
Published: (2021-07-01)

Effects of immunization against PCSK9 in an experimental model of breast cancer
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-04-01)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
by: Minglu Ma, et al.
Published: (2023-03-01)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
by: Giovanni Ciccarelli, et al.
Published: (2018-03-01)

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
by: Maciej Banach, et al.
Published: (2021-10-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies
by: Ngan T Tran, et al.
Published: (2015-04-01)

Effects of immunisation against PCSK9 in mice bearing melanoma
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

Berberine
by: Sarina Ataei, et al.
Published: (2022-08-01)

Carotenoid Interactions with PCSK9: Exploring Novel Cholesterol-Lowering Strategies
by: Alessandro Medoro, et al.
Published: (2024-11-01)

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
by: Claudette Cantin, et al.
Published: (2022-04-01)

Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol
by: Francine Sirois, et al.
Published: (2017-03-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
by: Markus Mohaupt
Published: (2016-07-01)

Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-04-01)

PCSK9 is not secreted from mature differentiated intestinal cells
by: Moreau François, et al.
Published: (2021-01-01)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

The influence of end-stage kidney failure on the composition of native blood lipoprotein complexes in men and women
by: A.S. Osochuk, et al.
Published: (2022-12-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
by: Christopher LaFratte, et al.
Published: (2023-09-01)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023-12-01)

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis
by: Dong Liu, et al.
Published: (2024-09-01)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020-08-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy
by: Kui Huang, et al.
Published: (2021-06-01)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
by: Xiang Zhang, et al.
Published: (2020-05-01)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE−/− Mice
by: Ping Jin, et al.
Published: (2021-10-01)

PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
by: Victoria Marco-Benedí, et al.
Published: (2024-09-01)

Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
by: Satoshi Yamashita, et al.
Published: (2023-05-01)